10.8.2018 Rare Daily Staff The U.S. Food and Drug Administration approved Revcovi, Leadiant Biosciences’ enzyme replacement therapy for the… Continue Reading
10.8.2018 Rare Daily Staff The European Medicines Agency granted Orchard Therapeutics Priority Medicines (PRIME) designation to OTL-300, an… Continue Reading
10.1.2018 Rare Daily Staff Black Africans have a higher level of Lupus than previous known and identified an antibody previously unlinked to the… Continue Reading
9.25.2018 Rare Daily Staff The National Institutes of Health said it would provide about $100 million in grants over the next four years to expand its… Continue Reading
9.20.2018 Rare Daily Staff Amicus Therapeutics agreed to acquire Celenex in a deal that provides it worldwide development and commercial rights for… Continue Reading
FDA Grants Cellectar Biosciences Rare Pediatric Disease Designation for Experimental Osteosarcoma Drug
9.19.2018 Rare Daily Staff The U. S. Food and Drug Administration has granted Rare Pediatric Disease designation to Cellectar Biosciences for its… Continue Reading
9.18.2018 When the European Medicines Agency approved Myozyme in 2006, Genzyme’s enzyme replacement therapy for the lysosomal storage disorder… Continue Reading
